ANCA-associated vasculitis therapy options mature around avacopan
Avacopan commercial maturity, rituximab maintenance protocols, and emerging mechanism programs are restructuring ANCA-associated vasculitis management.
ANCA-associated vasculitis has been a high-dose corticosteroid plus rituximab or cyclophosphamide induction category. Avacopan (C5a receptor antagonist) carries approval for severe active ANCA-associated vasculitis and substantially reduces the glucocorticoid dose needed for induction therapy, rituximab maintenance protocols are now structured, and emerging mechanism programs (BAFF-targeted, JAK pathway, others) are in late-stage trials.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- ExplainedWhat is lupus nephritis?
- SnapshotLupus nephritis therapy reference (2026)